Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Liebman discusses thrombosis in adult patients with chronic idiopathic thrombocytopenic purpura at EHA 2014.
GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the Chairs & speakers and provided input into the symposium agenda/content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Synthetic biology and precision medicine in blood and gynaecological cancers
Relapsed refractory multiple myeloma
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer